

Your guide for self-advocacy with Esperoct®

Have you ever felt frustrated or not heard when advocating for your hemophilia treatment needs?

Sharing your concerns with your healthcare provider (HCP) can feel intimidating, and starting those conversations takes practice. When getting ready for your next appointment, this guide can prepare you for self-advocacy by helping you:

- Reflect on your goals and needs
- Discuss how your treatment needs have changed
- Keep a record of any bleeding episodes to bring to your appointment
- Share the features of another treatment option
- Gain confidence in shared decision-making

Bradley has severe hemophilia A and uses Esperoct®.



According to the World Federation of Hemophilia (WFH), people with hemophilia are experts in their own hemophilia care through day-to-day self-management. It is important that their preferences, values, and personal experiences are considered in decision-making.

WHAT IS ESPEROCT®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

- Esperoct® is not used to treat von Willebrand Disease

IMPORTANT SAFETY INFORMATION

Who should not use Esperoct®?

- You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.



esperoct®

*antihemophilic factor (recombinant),
glycopegylated-exei*

Identifying your treatment needs

When asking your HCP about another treatment option, they may want to know how your bleeds, lifestyle, or treatment goals have changed. In addition to tracking and documenting your bleeds (which can be done on an app, on paper, or another method), you can prepare for your next visit by considering the self-advocacy tips below.

Know when and how to advocate for yourself

Getting started

List any changes since your last visit

Make a list of things to bring

Explain why making a change matters to you

"I am more active now, should I be considering a new treatment?"

"I have experienced changes in my day-to-day life since my last visit [eg, joining a running club]."

OR

"I have experienced a life change since my last visit [eg, I'm living away from home for the first time]."

- Examples of activities
- Lifestyle changes that may affect your current treatment
- Information about a treatment option you are considering
- Reasons why you think that treatment could be a good option
- Documentation such as your logbook and/or photos of bleeds

"When I feel confident that my hemophilia is under control, I am more comfortable doing my favorite activities."

Examples

Future health goals

• My lifestyle goals are:

• My treatment goals are:

• My desired treatment frequency is: On demand (when a bleed occurs) Prophylaxis (a set schedule to prevent bleeds)



Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.

Protection and flexibility on the go^a

Ready to ask your HCP about Esperoct®? Knowing the benefits of Esperoct® can help guide the conversation between you and your HCP. Check off the Esperoct® features boxes that you are interested in:

Flexibility with the highest storage temperature of all extended half-life products



Ready in 3 simple steps:



Prefilled diluent syringe contains 4 mL of diluent—works with any dose strength.



Adapter connects the syringe and vial with a 25 µm inline particle filter.



After mixing, the reconstituted solution can be administered in ~2 minutes.

Please see the complete Instructions for Use provided within the Prescribing Information.

Approved for all ages to use

Ability to use as prophylaxis or on demand



Simple prophylaxis dosing at a 50 IU/kg dose every 4 days for adults and adolescents (≥12) or a 65 IU/kg twice weekly for children under 12

See Prescribing Information for complete product storage information. Store reconstituted product in vial.

^aEsperoct® can be stored at room temperature up to 86 °F for up to 12 months or up to 104 °F for up to 3 months.

^bData shown are from 42 adults who received a pharmacokinetic assessment around the first Esperoct® 50 IU/kg dose.

^cComparison to prior Factor 8 product was performed at the beginning of the study in previously treated children. The geometric mean terminal half-life in 22 children aged 0 to 11 was 14.3 hours. Esperoct® geometric mean terminal half-life was 14.7 hours in 12 children aged 0 to 5 years old and 13.8 hours in 10 children aged 6 to 11 years old.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I need to know about Esperoct®?

- Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
- Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

rFVIII=recombinant Factor VIII.

Please see additional Important Safety Information throughout. Please see Prescribing Information at novo-pi.com/esperoct.pdf.

After reconstitution, Esperoct® can be:



Used up to **4 HOURS** at up to **86 °F**

OR



Stored in the refrigerator between **36 °F TO 46 °F** for up to **24 HOURS**

Compact packaging for easy storage with 5 vial sizes (500 IU, 1000 IU, 1500 IU, 2000 IU, and 3000 IU)



See Prescribing Information for complete product storage information.



Average half-life in adults^b

- Esperoct® is made by taking the existing Novoeight® (rFVIII) molecule and adding PEGylation technology to extend the half-life



Average half-life in children under 12^c

Studied in one of the largest and longest clinical trial programs with 270 previously treated patients over 80,000 infusion days

To learn more, visit www.esperoct.com

esperoct®
antihemophilic factor (recombinant),
glycopegylated-exei

TREATMENT DECISIONS ARE A TWO-WAY CONVERSATION

Remember—your HCP may be the clinical expert, but you are the expert on your experience living with hemophilia. Together, you can make treatment choices that are right for you.

Sharing questions and concerns with your HCP is an important part of open communication. Here are some questions that you can ask your HCP during your conversation:

- I'm not sure what you mean, could you please share more information?
- Can we talk through my treatment concerns?
- Could Esperoct® be a good treatment option for me?
- What types of changes would indicate a need to change treatment?
- Who should I contact if I have questions between appointments?

Tammy has hemophilia A and uses Esperoct®.



Visit esperoct.com to see how others benefit from treating with Esperoct®

Bring this guide with you to your next HCP visit—your needs are important and you deserve to be heard!

IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare provider before using Esperoct®?

- Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
- Your body can make antibodies called "inhibitors" against Esperoct®, which may stop Esperoct® from working properly. **Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®**

What are the possible side effects of Esperoct®?

- Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please see additional Important Safety Information throughout.
Please see Prescribing Information at novo-pi.com/esperoct.pdf.



Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Esperoct® and Novoeight® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2024 Novo Nordisk All rights reserved. US23ESP00074 January 2024

esperoct®
*antihemophilic factor (recombinant),
glycopegylated-exei*